CD47 Targeting Therapies Market: Poised for Soaring Growth Despite Cost Hurdles

CD47 Targeting Therapeutics Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1290

CD47 Targeting Therapeutics Market: High Growth Anticipated Despite Cost Challenges

Insight Analytics predicts a robust future for the global CD47 targeting therapeutics market, with a projected compound annual growth rate (CAGR) of 67% between 2022 and 2030.

CD47 is a transmembrane protein found on the surface of many cancer cells that plays a role in their survival. By binding to SIRP, CD47 triggers an inhibitory pathway that prevents macrophages from engulfing (phagocytosing) malignant cells. Inhibiting this CD47-SIRP interaction can therefore enhance tumor cell phagocytosis by macrophages.

Several factors are driving market growth:

• Aging population: A growing elderly population is more susceptible to cancer, increasing the demand for novel treatment options.

• Rising cancer rates: The high incidence of various cancers fuels the need for effective therapies.

• Increasing use of CD47-targeted therapies: As the benefits of CD47 targeting drugs become more recognized, their use is expected to rise.

• Growing public awareness: Public awareness of the potential of CD47 targeted therapies is creating a more informed patient population.

• Rising R&D investment: Increased research funding is propelling advancements in understanding CD47 signaling, paving the way for innovative anti-tumor therapies.

However, the market also faces challenges:

• High production costs: The complex manufacturing process of these targeted therapies makes them expensive.

• Potential side effects: Ensuring treatment effectiveness while minimizing damage to healthy cells remains a concern.

• Stringent regulations: Strict government approval processes can slow down market entry for new therapies.
Despite these hurdles, North America is expected to be a major market contributor due to its rapid adoption of new drugs and therapies, coupled with a high number of cancer patients. Additionally, the Asia Pacific region is anticipated to see significant growth driven by rising cancer rates, an aging population, and increasing awareness of CD47 targeted therapies.

Major market players operating in the CD47 Targeting Therapeutics market include
Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.

Recent collaborations and agreements in the market:

• In January 2022, the next-generation CD47 blocker evorpacept, manufactured by ALX Oncology, was accorded orphan drug designation ("ODD") for treating patients with gastroesophageal junction and gastric cancer.

• In September 2021, for US$2.3 billion, Pfizer Inc. (US) purchased Trillium Therapeutics Inc. (Canada), which had CD47 prospects. Pfizer now has a stronger cancer and hematology portfolio thanks to this acquisition.

• In June 2021, to test the efficacy of combining ALX148, a next-generation CD47 blocker, and CYRAMZA (ramucirumab), Lilly's anti-VEGFR2 antibody, for the treatment of gastric cancer, ALX Oncology (US) and Eli Lilly and Company (US) agreed into a clinical study partnership and supply agreement.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1290

Market Segments
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)

• Acute Myeloid Leukemia
• Non-Hodgkin Lymphoma
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndromes
• Non-Small Cell Lung Cancers
• Ovarian Epithelial Cancer
• Oral mucositis
• Small Cell Lung Cancers
• Other Diseases Indications

Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)

• Biologics
• Small Molecule

Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• U.S.
• Canada

Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global CD47 Targeting Therapeutics market
 To receive an industry overview and future trends in the CD47 Targeting Therapeutics market
 To analyze the CD47 Targeting Therapeutics market drivers and challenges
 To get information on the CD47 Targeting Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the CD47 Targeting Therapeutics market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1290

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.